Physician profile
Mark A Roberts
NPI 1275565442
$12,620.06
in general payments reported to CMS, 2019-2025
47 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,253 · 2020: $1,823 · 2021: $2,141 · 2022: $2,151 · 2023: $1,786 · 2024: $1,375 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,209 · Education: $42.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,208.55 |
| Education | $42.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,497.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,104.99 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,100.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $949.12 | 2019-2024 | Xarelto |
| Pfizer INC. | $860.18 | 2019-2025 | |
| Novo Nordisk INC | $847.27 | 2019-2024 | Rybelsus, Wegovy, Ozempic |
| Abbvie INC. | $718.13 | 2020-2025 | Ubrelvy |
| Amarin Pharma, INC. | $540.85 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $505.10 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.83 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Scilex Pharmaceuticals INC. | $406.26 | 2021-2024 | Ztlido |
| Bayer Healthcare Pharmaceuticals INC. | $391.98 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $381.24 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $331.43 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $282.23 | 2019-2025 | Eliquis |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.